pcna

PCNA-I1 is an inhibitor targeting PCNA chromatin association in prostate cancer.

AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC). It interferes with the interaction of PCNA with its binding proteins, leading to DNA replication stress and apoptosis. AOH1996 causes proteasome-dependent rpb1 degradation and lethal DNA damage by stabilizing the interaction between PCNA and RNA polymerase II, and acts synergistically with DNA damaging agents to inhibit tumor cell growth.

PCNA-IN-1 (Compound 11) is an inhibitor of the PCNA PIP-box interaction, with an IC50 greater than 50 μM. It is applicable in cancer research.

AOH1160 is an inhibitor of proliferating cell nuclear antigen (PCNA). AOH1160 induces apoptosis and causes cell-cycle arrest by interfering with DNA replication.

(S)-10-Hydroxycamptothecin (10-HCPT) is a DNA topoisomerase I inhibitor used as a clinical therapeutic agent against hepatoma.

ML323 is a reversible and effective USP1-UAF1 inhibitor in a Ub-Rho assay (IC50: 76 nM) and in orthogonal gel-based assays using K63-linked diubiquitin (di-Ub) (IC50: 174 nM 820 nM)and monoubiquitinated PCNA (Ub-PCNA) (IC50: 820 nM) as substrates, respectively.

Linuron, a substituted phenylurea herbicide, primarily functions by disrupting the photosynthetic process through the inhibition of photosystem II. it additionally acts as an androgen receptor antagonist, exhibiting endocrine-disrupting effects and reproductive toxicity, Maternal linuron exposure alters testicular development in male offspring at the whole genome level and significantly altering expressions of key testosterone synthesis-associated genes including Star, P450scc, 3β-Hsd, Abp, Cox7a2, Pcna, p450c17, and 17β-Hsd.

T2AA (4-[4-[(2S)-2-amino-3-hydroxypropyl]-2,6-diiodophenoxy]phenol) is an inhibitor of proliferating cell nuclear antigen (PCNA) with IC50 of 1 μM for PCNA PIP-box peptide interaction. T2AA suppresses cancer cell growth and causes DNA replication stress by stalling DNA replication forks and inhibiting PCNA interaction with DNA polymerase δ.

1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.

I-138 is an orally active and potent reversible inhibitor of USP1-UAF1.I-138 induces mono-ubiquitination of FANCD2 and PCNA and inhibits USP1 auto-cleavage in cells.

T2AA, a proliferating cell nuclear antigen (PCNA) inhibitor, disrupts protein-protein interactions between PCNA and both a PIP-box-containing peptide (IC50= 1 μM) and full-length p21, reducing cellular colocalization of PCNA with DNA polymerase δ. This compound effectively inhibits DNA replication and cell proliferation in U2OS and HeLa cells in a concentration-dependent manner, additionally inducing S phase cell cycle arrest at a 20 μM concentration. Furthermore, T2AA enhances DNA double strand break formation alongside cisplatin in a neutral comet assay and augments cisplatin-induced reductions in clonogenic survival in HeLa and U2OS cells.

13C-d3-AOH1996 is the 13C and deuterated compound of AOH1996. 13C-AOH1996 has a CAS number of 2089314-64-5. AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC).AOH1996 interferes with the interaction of PCNA with its binding proteins, leading to DNA replication stress and apoptosis.AOH1996 causes proteasome-dependent rpb1 degradation and lethal DNA damage by stabilizing the interaction between PCNA and RNA polymerase II.AOH1996 acts synergistically with DNA damaging agents to inhibit tumor cell growth. AOH1996 inhibits tumor cell growth by stabilizing the interaction between PCNA and RNA polymerase II, leading to proteasome-dependent rpb1 degradation and lethal DNA damage.AOH1996 acts synergistically with DNA damaging agents.

AOH-d3 is a deuterated compound of AOH. AOH has a CAS number of 2089314-64-5. AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC).AOH1996 interferes with the interaction of PCNA with its binding proteins, leading to DNA replication stress and apoptosis.AOH1996 causes proteasome-dependent rpb1 degradation and lethal DNA damage by stabilizing the interaction between PCNA and RNA polymerase II.AOH1996 acts synergistically with DNA damaging agents to inhibit tumor cell growth. AOH1996 inhibits tumor cell growth by stabilizing the interaction between PCNA and RNA polymerase II, leading to proteasome-dependent rpb1 degradation and lethal DNA damage.AOH1996 acts synergistically with DNA damaging agents.

p21PBP, a peptide composed of 20 amino acids, serves as an inhibitor of DNA replication. It specifically binds to the purified proliferating cell nuclear antigen (PCNA) found in extracts from tumor cells. p21PBP holds potential for use in cancer research.